Sargramostim, an innate immune system modulator, has been FDA approved for treating leukopenia for many years. Sargramostim has been investigated in this phase 2 study to determine if it can safely halt or reduce cognitive decline and brain pathology in participants with mild-to-moderate Alzheimer’s disease.
Prof. Huntington Potter (University of Colorado, Denver, MS, USA) joins touchNEUROLOGY to discuss the phase 2 results (NCT01409915) to investigate whether inflammation and the innate immune system in Alzheimer’s disease may provide therapeutic benefit, and what will be the next steps in the development of sargramostim in Alzheimer’s disease.
- Could you tell us a little about sargramostim, its mechanism of action and clinical uses? (0:18)
- What is the rationale for investigating sargramostim in the setting of Alzheimer’s disease (AD)? (1:15)
- What were the aims, design and primary outcome measures of your study? (3:25)
- What will be the next step in the clinical development of sargramostim in AD? (5:52)
- What are the take home messages from your presentation? (7:58)
Disclosures: Huntington Potter has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AD/PD 2022.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Claire Sexton: Highlights of AAIC 2022
The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing Alzheimer’s and dementia research. Each year, it gathers researchers to share discoveries that’ll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. Dr Claire Sexton is the senior director of Scientific Programs […]
Dr Jennifer Bute: Living with dementia – the importance of laughter and hope
Dr Jennifer Bute is a retired GP living with dementia. She shares her experiences of diagnosis and describes the strategies that are helpful for her. Jennifer also highlights the importance of laughter, engagement and hope. Touch Medical Media is sharing educational resources on World Brain Day (22 July 2022) to help achieve brain health for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!